Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00023894 · ClinicalTrials.gov registry record · Phase 2
Flavopiridol in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase 2 study, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00023894 is a Phase 2 study that has completed, run by Gynecologic Oncology Group.
The verdict
NCT00023894, a Phase 2 study, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of flavopiridol in treating patients who have recurrent or persistent endometrial cancer.
Interventions
- DRUG alvocidib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-07 |
| Est. Completion | 2006-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00023894
The ClinicalTrials.gov registry entry for NCT00023894 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which alvocidib is the first listed.
NCT00023894 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00023894 about?
NCT00023894 is a clinical study titled "Flavopiridol in Treating Patients With Recurrent or Persistent Endometrial Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of flavopiridol in treating patients who have recurrent or persistent endometrial cancer.
What is the current status of trial NCT00023894?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-07. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00023894?
The interventions under investigation include: alvocidib (DRUG).
Who is sponsoring clinical trial NCT00023894?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.